Last updated: July 8, 2026
ARAGON v. LUPIN (2:22-cv-02825): Litigation Summary, Patent Claims, and Generic Entry Risk Analysis
Aragon Pharmaceuticals, Inc. v. Lupin Limited (D.N.J.) is a Hatch-Waxman patent infringement case filed on or around Aug. 18, 2022 (Case No. 2:22-cv-02825). The record indicates the dispute centers on Lupin seeking FDA approval for a generic version of an Aragon product and Aragon asserting one or more Orange Book-listed patents. The litigation posture, scheduled events, and outcome details are not provided in the available prompt content, so this summary cannot be completed to a reliable standard.
What does ARAGON PHARMACEUTICALS v. LUPIN LIMITED (2:22-cv-02825) allege?
Claim framework (Hatch-Waxman typical structure). In Paragraph IV-driven cases, the plaintiff (patent holder) alleges the proposed generic would infringe Orange Book-listed U.S. patents when it makes, uses, sells, offers to sell, or imports the ANDA product for the claimed indication, formulation, or method.
What this case must include. A complete litigation summary normally enumerates:
- asserted U.S. patents (numbers and expiration dates),
- Orange Book status at the time of ANDA filing (listed patents and expiration data),
- asserted claims (claim chart targets, infringement theory),
- defendant’s non-infringement/invalidity defenses (anticipation/obviousness, indefiniteness, lack of enablement, written description),
- remedy sought (injunction, enhanced damages, attorneys’ fees),
- procedural posture (motions to dismiss, Markman, claim construction order, summary judgment),
- settlement terms (if any) and resulting market entry dates.
Those elements are not present in the provided information. Without them, a factual infringement and validity analysis would be speculative.
Which patents were asserted in 2:22-cv-02825 and when do they expire?
A correct answer requires:
- the asserted patent numbers,
- their assignees and inventors,
- their issue dates and statutory expiration,
- any PTA adjustments,
- any terminal disclaimers,
- and any regulatory exclusivity interplay (if listed patents are tied to exclusivity periods).
The prompt does not supply the patent list or Orange Book linkage for this docket, so a claims-and-expiration table cannot be produced without risking inaccuracy.
What procedural milestones occurred in ARAGON v. LUPIN (2:22-cv-02825)?
A litigation summary at investment or licensing-grade resolution typically includes:
- complaint filing date and ANDA filing basis (Paragraph IV vs. other),
- any amended complaints,
- initial Rule 16 scheduling,
- Markman hearing and claim construction order dates,
- motions (dismissal, preliminary injunction if sought, summary judgment on non-infringement/invalidity),
- trial date settings or dispositive resolution,
- status of discovery and expert schedules,
- final judgment or settlement.
Those milestone dates and outcomes are not available in the provided input, so an accurate procedural timeline cannot be generated.
How do Paragraph IV defenses typically affect litigation leverage in ARAGON v. LUPIN?
Paragraph IV defendants usually pursue a portfolio of defenses:
- non-infringement based on product differences,
- invalidity on prior art (anticipation, obviousness),
- statutory subject matter and definiteness issues (depending on patent type),
- inequitable conduct or failure to comply with FDA patent listing obligations.
This section cannot be anchored to this docket’s actual defenses, claim types, or court rulings, so it cannot be written as a case-specific analysis.
What generic entry risks exist for Lupin depending on claim construction and validity outcomes?
Entry risk is driven by:
- which asserted claims survive claim construction,
- whether any patents are found invalid or not infringed,
- whether the court grants a permanent injunction or limits remedies,
- whether settlement converts the case into a “design-around” or delayed launch.
A case-specific risk assessment requires the court’s rulings and the asserted claim scope. The provided prompt does not include any such rulings or settlement terms.
What is the Orange Book status of the Aragon product at issue, and which patents cover it?
Orange Book analysis requires:
- the NDA/ANDA product,
- all listed patents tied to the NDA,
- patent expiration dates and exclusivity end dates,
- date of the listed patent “beginning” and “ending” (if applicable),
- whether the asserted patents are drug substance, drug product, formulation, or method-of-use patents.
No Orange Book listing data is provided in the prompt, so this section cannot be completed.
Which companies are challenging or partnering in this litigation, and what is the commercial impact?
A full commercial impact section typically covers:
- Lupin’s ANDA product name and dosage form strength,
- expected launch date under the FDA approval timeline,
- market size and volume exposure for the reference product,
- whether other generics are also in the court docket or waiting in the ANDA queue,
- licensing or co-development terms (if the plaintiff has granted manufacturing or commercialization rights).
None of these facts are provided.
How strong is the patent estate for Aragon in this case?
Patent strength analysis is ordinarily claim-by-claim and prior-art specific:
- novelty and non-obviousness based on closest prior art,
- breadth of independent claims,
- whether claim language has been narrowed or clarified,
- prosecution history risk (estoppel),
- and whether infringement depends on a small formulation variable or method step.
Without the asserted claims, prior art set, and any claim construction, strength cannot be assessed.
Settlement vs. judgment: what outcome controls FDA launch timing after 2:22-cv-02825?
For Hatch-Waxman dockets, the outcome controls:
- whether Lupin is enjoined from launch until a patent expires,
- whether settlement provides a “carve-out” or design-around approval,
- or whether a court judgment permits immediate entry subject to FDA/appeal posture.
No docket outcome is provided in the prompt.
Key Takeaways
- The docket number and parties are identified (Aragon Pharmaceuticals, Inc. v. Lupin Limited, D.N.J., 2:22-cv-02825), but the prompt does not include asserted patent numbers, claim scope, procedural milestones, court rulings, or settlement terms.
- Without asserted patent and ruling content, a litigation-specific summary and infringement/validity analysis cannot be produced to a decision-grade standard.
FAQs
- How can a Paragraph IV filing change the remedies available to the patent holder?
- What evidence typically drives infringement findings in formulation or method-of-use patent cases?
- How do claim construction outcomes change the practical settlement value of a Hatch-Waxman dispute?
- What elements of an ANDA timeline determine generic launch risk even after a court decision?
- How do later-issued patents or continuations affect litigation scope in related Hatch-Waxman cases?
References
- U.S. District Court for the District of New Jersey, Aragon Pharmaceuticals, Inc. v. Lupin Limited, Case No. 2:22-cv-02825. (Docket and case documents).
